Skip to main content

Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2018-2022 | Increasing Prevalence of DLBCL to Spur Growth | Technavio

Technavio analysts forecast the global diffuse large B-Cell lymphoma therapeutics market to grow at a CAGR of close to 8% during the forecast period, according to their latest market research report.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181019005372/en/

Technavio analysts forecast the global diffuse large B-Cell lymphoma therapeutics market to grow at  ...

Technavio analysts forecast the global diffuse large B-Cell lymphoma therapeutics market to grow at a CAGR of close to 8% by 2022. (Graphic: Business Wire)

The rising technological advances are one of the major trends being witnessed in the global diffuse large B-Cell lymphoma therapeutics market 2018-2022. Companies are focusing on developing new technologies and innovative therapies, which can overcome the current challenges in the treatment of various cancers, including DLBCL. Currently, innovative therapies such as chimeric antigen receptor (CAR) T cell therapy, gene therapy, companion diagnostics, and personalized medicines are being developed at a rapid pace for the treatment of DLBCL. These latest therapies are more effective and reduce the efforts applied in the treatment.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

According to Technavio analysts, one of the key factors contributing to the growth of the global diffuse large B-Cell lymphoma therapeutics market is the increasing incidence of DLBCL:

Global diffuse large B-Cell lymphoma therapeutics market: Increasing incidence of DLBCL

DLBCL is the fast-growing and common type of Non-Hodgkin Lymphoma (NHL) cancer among adults. The incidence of DLBCL is increasing globally and can be fatal if untreated. The prevalence of the disease is mainly due to changing food habits and lifestyle which causes unusual changes in the body such as the growth of lymphocytes that reproduce or divide.

According to a senior analyst at Technavio for research on infectious and rare diseases, “DLBCL is more prevalent in men than women. For instance, as per CDC, NHL is one of the ten types of commonly caused cancers. About 67,522 cases were reported in 2015, among which about 55% of the cases were found in men.”

Global diffuse large B-Cell lymphoma therapeutics market: Segmentation analysis

The global diffuse large B-Cell lymphoma therapeutics market research report provides market segmentation by product (small molecules and biologics) and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Of the two major products, small molecules and biologics, the small molecules segment held the largest market share in 2017, contributing to over 61% of the market. This product segment will continue to dominate the global market throughout the forecast period.

The Americas held the largest share of the market in 2017, accounting for close to 47% share, followed by EMEA and APAC respectively. The region is expected to continue to dominate the market during the forecast period.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts:

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.